Theravance Vibativ OK'd in hospital/ventilator pneumonia
This article was originally published in Scrip
Executive Summary
Share ofTheravance got an added 2% boost going into the weekend after the US FDA gave its blessing for the South San Francisco biotech’s antibiotic Vibativ (telavancin) as a treatment in adults with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable.